Article
Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients.
International journal of molecular sciences - 13 Mar 2017
Liu Jing, Chen Zhiyu, Chen Hanmei, Hou Yingyong, Lu Weiqi, He Junyi, Tong Hanxing, Zhou Yuhong, Cai Weimin
Abstract excerpt
Imatinib mesylate (IM) has dramatically improved the outcomes of gastrointestinal stromal tumor (GIST) patients. However, the clinical responses of IM may considerably vary among single individuals. This study aimed to investigate the influences of genetic polymorphisms of drug-metabolizing enzyme (CYP3A4), transporters (ABCB1, ABCG2), and nuclear receptor (Pregnane X Receptor (PXR, encoded by NR1I2)) on IM...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
